Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Posted by Geri Gentry on Aug 21st, 2026

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the senior vice president owned 1,274 shares in the company, valued at $127,400. This represents a 96.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Jolanda Howe also recently made the following trade(s):

On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $105.29, for a total transaction of $193,733.60.
On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00.
On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $97.07 on Friday. The company has a market capitalization of $6.30 billion, a PE ratio of -6.67 and a beta of 0.52. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a twelve month low of $63.23 and a twelve month high of $130.00. The firm has a fifty day simple moving average of $111.26 and a 200 day simple moving average of $101.98.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.Mirum Pharmaceuticals’s quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) earnings per share. On average, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. ABS Investment Management LLC bought a new position in Mirum Pharmaceuticals in the 2nd quarter valued at about $245,847,000. Quantbot Technologies LP bought a new stake in Mirum Pharmaceuticals during the 2nd quarter worth approximately $44,000. Cullen Frost Bankers Inc. bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on MIRM. Citizens Jmp dropped their price objective on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating on the stock in a report on Thursday, August 6th. Morgan Stanley set a $137.00 target price on Mirum Pharmaceuticals in a research note on Thursday, August 6th. Royal Bank Of Canada decreased their target price on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a report on Monday, June 15th. Finally, Evercore reissued an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $137.33.

Get Our Latest Stock Analysis on MIRM

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.